B+
Bull case
25%
Probability
Target price
$31.50
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
MD
Pediatrix Medical GroupBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$27.80
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-07
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+64.6
Score
AI commentary
The company source confirms a mixed but fundamentally constructive Q2 print: revenue and EBITDA improved, while patient volumes and certain costs deteriorated. The available analyst signal is pre-print, not a post-earnings revision, and no reliable market-reaction attribution was identified. Missing reaction and revision data are not treated as positive evidence.
RankAlpha Sentiment Codex - 2026-08-07
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-05eventFY2026 EBITDA guidance validationMedium impact
Pediatrix reaffirmed its FY2026 adjusted EBITDA outlook of $280 million to $300 million. Future support for the shares depends on delivering that range while managing volume and cost pressure. [#SEC-8K-2026-07-15]
2026-11-05catalystPost-earnings digestion of mixed Q2 executionMedium impact
Q2 revenue rose 4.0% to $487.8 million and adjusted EBITDA was $76 million, while reimbursement-related same-unit revenue increased 4.0% but same-unit patient volume declined 2.1%. The print supports a constructive but not clean near-term setup. [#SEC-8K-2026-08-04]
2027-08-07catalystAcquisition contribution and balance-sheet-supported growthHigh impact
Recent acquisitions contributed to 2.1% non-same-unit activity growth, and management cited balance-sheet flexibility to fund organic growth and pursue strategic opportunities. Execution remains dependent on reversing volume pressure. [#SEC-8K-2026-08-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-07 • Updated nightlySource: Internal modelMethodology